Literature DB >> 30465669

Nanomedicine and macroscale materials in immuno-oncology.

Qingxue Sun1, Matthias Barz, Bruno G De Geest, Mustafa Diken, Wim E Hennink, Fabian Kiessling, Twan Lammers, Yang Shi.   

Abstract

Immunotherapy is revolutionizing the treatment of cancer. It can achieve unprecedented responses in advanced-stage patients, including complete cures and long-term survival. However, immunotherapy also has limitations, such as its relatively low response rates and the development of severe side effects. These drawbacks are gradually being overcome by improving our understanding of the immune system, as well as by establishing combination regimens in which immunotherapy is combined with other treatment modalities. In addition to this, in recent years, progress made in chemistry, nanotechnology and materials science has started to impact immuno-oncology, resulting in more effective and less toxic immunotherapy interventions. In this context, multiple different nanomedicine formulations and macroscale materials have been shown to be able to boost anti-cancer immunity and the efficacy of immunomodulatory drugs. We here review nanotechnological and materials chemistry efforts related to endogenous and exogenous vaccination, to the engineering of antigen-presenting cells and T cells, and to the modulation of the tumor microenvironment. We also discuss limitations, current trends and future directions. Together, the insights provided and the evidence obtained indicate that there is a bright future ahead for engineering nanomedicines and macroscale materials for immuno-oncology applications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30465669      PMCID: PMC7115880          DOI: 10.1039/c8cs00473k

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   54.564


  126 in total

Review 1.  Hydrogels for protein delivery.

Authors:  Tina Vermonden; Roberta Censi; Wim E Hennink
Journal:  Chem Rev       Date:  2012-02-23       Impact factor: 60.622

2.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

Authors:  Yiran Zheng; Li Tang; Llian Mabardi; Sudha Kumari; Darrell J Irvine
Journal:  ACS Nano       Date:  2017-03-01       Impact factor: 15.881

Review 3.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 4.  Cancer immunotherapy via dendritic cells.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events.

Authors:  Jun Ishihara; Kazuto Fukunaga; Ako Ishihara; Hans M Larsson; Lambert Potin; Peyman Hosseinchi; Gabriele Galliverti; Melody A Swartz; Jeffrey A Hubbell
Journal:  Sci Transl Med       Date:  2017-11-08       Impact factor: 17.956

6.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

Review 7.  Systemic effects of local radiotherapy.

Authors:  Silvia C Formenti; Sandra Demaria
Journal:  Lancet Oncol       Date:  2009-07       Impact factor: 41.316

8.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Authors:  Marco Ruella; Jun Xu; David M Barrett; Joseph A Fraietta; Tyler J Reich; David E Ambrose; Michael Klichinsky; Olga Shestova; Prachi R Patel; Irina Kulikovskaya; Farzana Nazimuddin; Vijay G Bhoj; Elena J Orlando; Terry J Fry; Hans Bitter; Shannon L Maude; Bruce L Levine; Christopher L Nobles; Frederic D Bushman; Regina M Young; John Scholler; Saar I Gill; Carl H June; Stephan A Grupp; Simon F Lacey; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440

9.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

10.  Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer.

Authors:  Jutaek Nam; Sejin Son; Lukasz J Ochyl; Rui Kuai; Anna Schwendeman; James J Moon
Journal:  Nat Commun       Date:  2018-03-14       Impact factor: 14.919

View more
  17 in total

1.  Smart cancer nanomedicine.

Authors:  Roy van der Meel; Einar Sulheim; Yang Shi; Fabian Kiessling; Willem J M Mulder; Twan Lammers
Journal:  Nat Nanotechnol       Date:  2019-11-06       Impact factor: 39.213

2.  Combining Nanomedicine and Immunotherapy.

Authors:  Yang Shi; Twan Lammers
Journal:  Acc Chem Res       Date:  2019-05-23       Impact factor: 22.384

Review 3.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

4.  Deep exploration of random forest model boosts the interpretability of machine learning studies of complicated immune responses and lung burden of nanoparticles.

Authors:  Fubo Yu; Changhong Wei; Peng Deng; Ting Peng; Xiangang Hu
Journal:  Sci Adv       Date:  2021-05-26       Impact factor: 14.136

Review 5.  Nanotechnology synergized immunoengineering for cancer.

Authors:  Deepak S Chauhan; Anupam Dhasmana; Partha Laskar; Rajendra Prasad; Nishant K Jain; Rohit Srivastava; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Eur J Pharm Biopharm       Date:  2021-03-24       Impact factor: 5.589

Review 6.  Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy.

Authors:  Ki-Taek Kim; Jae-Young Lee; Dae-Duk Kim; In-Soo Yoon; Hyun-Jong Cho
Journal:  Pharmaceutics       Date:  2019-06-14       Impact factor: 6.321

Review 7.  Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics.

Authors:  Simon Van Herck; Bruno G De Geest
Journal:  Acta Pharmacol Sin       Date:  2020-05-25       Impact factor: 6.150

Review 8.  Cancer nanomedicine meets immunotherapy: opportunities and challenges.

Authors:  Qingxue Sun; Xiangyang Bai; Alexandros Marios Sofias; Roy van der Meel; Eduardo Ruiz-Hernandez; Gert Storm; Wim E Hennink; Bruno De Geest; Fabian Kiessling; Hai-Jun Yu; Twan Lammers; Yang Shi
Journal:  Acta Pharmacol Sin       Date:  2020-06-17       Impact factor: 6.150

Review 9.  Engineering Nanoparticles to Reprogram the Tumor Immune Microenvironment for Improved Cancer Immunotherapy.

Authors:  Madiha Saeed; Jing Gao; Yang Shi; Twan Lammers; Haijun Yu
Journal:  Theranostics       Date:  2019-10-17       Impact factor: 11.556

Review 10.  Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics.

Authors:  Peng Mi
Journal:  Theranostics       Date:  2020-03-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.